Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » The Scan » Now, Developer

Now, Developer

Jan 13, 2020

23andMe has licensed an antibody it developed to treat inflammatory diseases to the Spanish drugmaker Almirall, according to Bloomberg. 

"This is a seminal moment for 23andMe," Emily Drabant Conley, the vice president of business development at 23andMe, tells Bloomberg. "We've now gone from database to discovery to developing a drug."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Working Out the Effect

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Increased Genetic Privacy in Florida

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

Attention-Grabbing in Two Ways

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

Nature Papers Describe CRISPR Plant Editing Methods, DNA-PAINT Improvements, More

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.

What's Popular?

In Business News

  1. Centogene Gets Emergency Use Authorization for PCR-Based Coronavirus Test

  2. Invitae Stock Skyrockets in June on ArcherDx Acquisition, Leading GenomeWeb Index

  3. Surge in Stocks of SARS-CoV-2 Dx Developers Pushes GenomeWeb Index Up 15 Percent in H1 2020

  4. Hitachi, ThinkCyte Partner to Develop AI-Driven Cell Analysis, Sorting System

  5. FDA Issues Warning Letter to Luminex

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.